Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 7/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-En-Metabolite SCHEMBL9111371 | 1.00 | CHRM1 (0.62) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL2081268 | 0.88 | CA2 (0.61) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL570260 | 0.88 | CA2 (0.61) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL8567555 | 0.86 | CA2 (0.59) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9239263 | 0.86 | CA2 (0.53) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL584897 | 0.86 | CA2 (0.53) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9237929 | 0.86 | CA2 (0.53) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL8572261 | 0.86 | CA2 (0.59) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5363929 | 0.84 | CHRM1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL4940873 | 0.84 | GRIK1 (0.54) | GRIK1GRIK2CPA1SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577789-A | Method for detecting 2-propyl-4-pentenoic acid in anti-epileptic drug valproic acid | 湖南省湘中制药有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-118638002-A | Preparation method of sodium valproate toxic metabolite 2-propyl-4-pentenoic acid | 湖南大学 | 2024-09-13 | — | — | CN | claimed |
| US-8722600-B2 | Polymers with H-bridge forming functionalities for improving anti-wear protection | EVONIK ROHMAX ADDITIVES GMBH (DE) | 2014-05-13 | — | — | US | claimed |
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| US-RE37670-E1 | Antiproliferative and neurotrophic molecules | AMERICAN BIOGENETICS INC. | 2002-04-23 | — | — | US | claimed |
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | NAU HEINZ (DE) | 2002-01-31 | — | — | US | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| US-5672746-A | UNSATURATED ALKYL CARBOXYLIC ACIDS(AND THEIR SALTS) FOR TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-09-30 | — | — | US | claimed |
| EP-0778820-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-06-18 | — | — | EP | claimed |
| WO-1996006821-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| JP-8012618-A | — | — | None | — | — | JP | disclosed |
| CN-121577789-A | Method for detecting 2-propyl-4-pentenoic acid in anti-epileptic drug valproic acid | 湖南省湘中制药有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-121577789-A | Method for detecting 2-propyl-4-pentenoic acid in anti-epileptic drug valproic acid | 湖南省湘中制药有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| WO-1994006743-A1 | ANALOGUES OF VPA USED AS ANTI-EPILEPTICA | NAU HEINZ (DE) | 1994-03-31 | — | — | WO | disclosed |
| US-4432985-A | N-alkylated carboxylic acid derivatives as anti-convulsant agents | ABBOTT LABORATORIES (US) | 1984-02-21 | — | — | US | disclosed |
| US-3932285-A | MONOCARBOXYLIC ACID | TENNECO CHEMICALS, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | CHRM1 93/4885AKR1A1 771/4885CHRM3 89/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | CHRM1 84/4885AKR1A1 976/4885CHRM3 129/4885 |
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | BDNF, NGF, NTRK2 | CHRM1 4273/4885AKR1A1 2994/4885CHRM3 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.